CN1098265C - Process for refining meloxicam - Google Patents
Process for refining meloxicam Download PDFInfo
- Publication number
- CN1098265C CN1098265C CN 01128086 CN01128086A CN1098265C CN 1098265 C CN1098265 C CN 1098265C CN 01128086 CN01128086 CN 01128086 CN 01128086 A CN01128086 A CN 01128086A CN 1098265 C CN1098265 C CN 1098265C
- Authority
- CN
- China
- Prior art keywords
- meloxicam
- hydro
- refining
- oxidation
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a new nonsteroidal antipyretic analgesic, particularly to a technology for refining meloxicam. The present invention especially comprises the following steps: 1) recrystallization of meloxicam: crude meloxicam is added in dimethylformamide (DMF) and heated so that the crude meloxicam is dissolved, decolorized and filtrated by activated carbon; filtered solutions are cooled to extract meloxicam crystals; 2) purification of the meloxicam: the meloxicam obtained by recrystallization is dissolved in alkali alcoholic solutions, dilute hydrochloric acids are dropped by stirring, the PH value of the solutions is regulated to two to three, the solutions are filtered, solids are collected and washed to neutrality, and finished products of the meloxicam are obtained. The present invention has the advantages of simple technology, high safety and no toxin; the present invention can effectively reduce the content of DMF in the finished products.
Description
Technical field
The present invention relates to a kind of new non-steroidal analgesic-antipyretic, be specially a kind of process for refining of meloxicam.
Background technology
Meloxicam is a kind of new non-steroidal analgesic-antipyretic, has higher anti-inflammatory activity and good especially enteron aisle tolerance, and does not have renal toxicity, and internally rheumatic arthritis and osteoarthritis have significant curative effect, go on the market at home in calendar year 2001.
United States Patent (USP) (US Pat.) 4,233,299 (1980), the process for purification that discloses a kind of meloxicam is to use tetrahydrofuran (THF) to carry out recrystallization, because the solubleness of meloxicam in tetrahydrofuran (THF) is little, this method need be used a large amount of recrystallization solvents, and the ratio of solvent and meloxicam reaches 50: 1 (v/w); In addition, tetrahydrofuran (THF) is a kind of inflammable and explosive organic appearance agent, and unstable in air, and the dangerously explosive superoxide of easy oxidized generation brings hidden danger to production safety, should avoid using.
It is recrystallization solvent (Xu Youjun that the another kind of process for purification of meloxicam is to use dimethyl formamide (DMF), Liu Feng; Yang Zhi Min, synthetic chemistry, 1999,7:118), though can the purifying meloxicam, dimethyl formamide content residual in the finished product is very high, usually above 1000ppm, the allowed band that is higher than Chinese Pharmacopoeia far away must manage to remove the dimethyl formamide in the finished product.
Summary of the invention
The object of the present invention is to provide that a kind of technology is simple, safety non-toxic, can effectively reduce the process for refining of the meloxicam of dimethyl formamide (DMF) content in the finished product.
Technical scheme of the present invention is to operate as follows:
1. with meloxicam recrystallization of dimethyl formamide (DMF), carry out preliminary purification:
With meloxicam first product and DMF (g) by weight: volume (mL) is to mix in 1: 5～1: 7, is heated to meloxicam is all dissolved, and use activated carbon decolorizing, filters, and the filtrate cooling is filtered up to separating out the meloxicam crystal fully, the collection solid;
2. with the meloxicam behind the preliminary purification, further handle, remove dimethyl formamide with alkaline alcohol solution:
The meloxicam that above-mentioned steps is obtained is (g) by weight: volume (mL) is to be dissolved in alkaline alcohol solution in 1: 1～1: 3 (wherein the concentration range of alkali is in 1～2mol/L), stir and drip dilute hydrochloric acid down, its concentration range is 5～7mol/L, being adjusted to the pH value of solution value is 2～3, filter, collect solid, use ethanol, water, water, washing with alcohol successively, obtain the meloxicam finished product to neutral;
Described alkaline alcohol solution is one of ethanol hydro-oxidation sodium, ethanol hydro-oxidation potassium, propyl alcohol hydro-oxidation sodium, propyl alcohol hydro-oxidation potassium, Virahol hydro-oxidation sodium and Virahol hydro-oxidation potassium.
Advantage of the present invention is as follows:
1. technology is simple.The present invention is directed to the bigger characteristics of meloxicam changes in solubility in DMF, adopted the DMF recrystallization, handle meloxicam in conjunction with alkaline alcohol solution simultaneously, the DMF that carries secretly in the meloxicam is dissolved in the alcohol and removes, the potential of hydrogen of re-adjustment solution is separated out meloxicam, has removed harmful DMF simply from the meloxicam first product, avoid using a large amount of inflammable and explosive tetrahydrofuran (THF)s, simplified the purifying process of meloxicam.
2. safety non-toxic.The ratio (v/w) of recrystallization solvent consumption of the present invention and meloxicam has dropped to 5: 1 from 50: 1, and the DMF security is better.
3. can effectively reduce the DMF content in the finished product.The present invention is owing to increased the alkaline alcohol solution treatment step, and the DMF content in the finished product is usually from reducing to below the 10ppm more than the 1000ppm.
Embodiment
Following example is specifically addressed the present invention, but is not limited thereto.
Embodiment 1
With the refining meloxicam of the alkaline dehydrated alcohol that contains sodium hydroxide, concrete steps are as follows:
1. the recrystallization of meloxicam:
20g meloxicam first product and 100mLDMF are placed the 250mL round-bottomed flask, be heated to meloxicam is all dissolved, use activated carbon decolorizing, filter, the filtrate cooling is filtered up to separating out the meloxicam crystal fully, collect solid, obtain 17g meloxicam crystal, the rate of recovery is not less than 80%;
2. the purifying of meloxicam:
Get the meloxicam solid 10g that the step obtains, be dissolved in the 20mL alkalescence dehydrated alcohol that contains 1.14g sodium hydroxide, stir down, drip dilute hydrochloric acid, its concentration is 6mol/L, to the pH value of solution value be 2, filter, collect solid, use ethanol, water, water, washing with alcohol successively to neutral, obtain meloxicam finished product 9.5 grams, the rate of recovery is not less than 90%.
Detect through combined gas chromatography mass spectrometry (GC-MS), the DMF residual quantity has been reduced to 8ppm from 1200ppm, has reached the requirement of Chinese Pharmacopoeia.
Embodiment 2
With the refining meloxicam of the alkaline dehydrated alcohol that contains potassium hydroxide, concrete steps are as follows:
1. adopt the method preliminary purification meloxicam of step 1 among the embodiment 1;
2. adopt the refining meloxicam of method of step 2 among the embodiment 1, its difference is: just change sodium hydroxide into potassium hydroxide, consumption is 1.59g, and the meloxicam finished product that obtains detects through GC-MS, the DMF residual quantity has been reduced to 8ppm from 1200ppm, has reached the requirement of Chinese Pharmacopoeia.
Embodiment 3
With the refining meloxicam of the alkaline propyl alcohol that contains sodium hydroxide, concrete steps are as follows:
1. get meloxicam first product 50 gram and DMF300mL, adopt the method preliminary purification meloxicam of step 1 among the embodiment 1, obtain meloxicam crystal 43 grams;
2. adopt the refining meloxicam of method of step 2 among the embodiment 1, its difference is: the meloxicam 35g that gets preliminary purification, change dehydrated alcohol into propyl alcohol, consumption is 100mL, and sodium hydrate content is 5.7g in the solution, dripping dilute hydrochloric acid to pH value of solution value is 3, dilute hydrochloric acid concentration is 5mol/L, obtains meloxicam finished product 32.8 grams, detects through GC-MS, the DMF residual quantity has been reduced to 8ppm from 1500ppm, has reached the requirement of Chinese Pharmacopoeia.
Embodiment 4
With the refining meloxicam of the alkaline Virahol that contains sodium hydroxide, concrete steps are as follows:
1. get meloxicam first product 120 gram and DMF800mL, adopt the method preliminary purification meloxicam of step 1 among the embodiment 1, obtain meloxicam crystal 104 grams;
2. adopt the refining meloxicam of method of step 2 among the embodiment 1, its difference is: the meloxicam 100g that gets preliminary purification, change dehydrated alcohol into Virahol, consumption is 100mL, and sodium hydrate content is 5.7g in the solution, dripping dilute hydrochloric acid to pH value of solution value is 3, dilute hydrochloric acid concentration is 7mol/L, obtains meloxicam finished product 92 grams, detects through GC-MS, the DMF residual quantity has been reduced to 8ppm from 2000ppm, has reached the requirement of Chinese Pharmacopoeia.
Solvent of the present invention is the commercially available prod, and it is as follows to originate:
Dimethyl formamide (DMF), the federal chemical reagent work in Shenyang City, Liaoning
Dehydrated alcohol, the federal chemical reagent work in Shenyang City, Liaoning
Propyl alcohol, the federal chemical reagent work in Shenyang City, Liaoning
Virahol, the federal chemical reagent work in Shenyang City, Liaoning
Reagent of the present invention is the commercially available prod, and it is as follows to originate:
Meloxicam, Shandong Xinhua Pharmaceutical Factory
Sodium hydroxide, the federal chemical reagent work in Shenyang City, Liaoning
Potassium hydroxide, the federal chemical reagent work in Shenyang City, Liaoning
Gac, extraordinary chemical reagent development centre, North China
Claims (2)
1. the process for refining of a meloxicam is characterized in that operating as follows:
1) with meloxicam recrystallization of dimethyl formamide, carry out preliminary purification:
With meloxicam first product and dimethyl formamide (g) by weight: volume (mL) is to mix in 1: 5～1: 7, is heated to meloxicam is all dissolved, and use activated carbon decolorizing, filters, and filtrate is cooled to the meloxicam crystal and separates out fully, filters the collection solid;
2) with the meloxicam behind the preliminary purification, further handle with alkaline alcohol solution, remove dimethyl formamide:
The meloxicam that above-mentioned steps is obtained is (g) by weight: volume (mL) is to be dissolved in the alkaline alcohol solution in 1: 1～1: 3, the concentration of alkali is 1～2mol/L in the described alkaline alcohol solution, stir and drip dilute hydrochloric acid down, its concentration range is 5～7mol/L, being adjusted to the pH value of solution value is 2～3, filters, and collects solid, use ethanol, water, water, washing with alcohol to neutral successively, obtain the meloxicam finished product.
2. according to the process for refining of the described meloxicam of claim 1, it is characterized in that: described alkaline alcohol solution is one of ethanol hydro-oxidation sodium, ethanol hydro-oxidation potassium, propyl alcohol hydro-oxidation sodium, propyl alcohol hydro-oxidation potassium, Virahol hydro-oxidation sodium and Virahol hydro-oxidation potassium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01128086 CN1098265C (en) | 2001-08-24 | 2001-08-24 | Process for refining meloxicam |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01128086 CN1098265C (en) | 2001-08-24 | 2001-08-24 | Process for refining meloxicam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1342650A CN1342650A (en) | 2002-04-03 |
| CN1098265C true CN1098265C (en) | 2003-01-08 |
Family
ID=4667980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01128086 Expired - Fee Related CN1098265C (en) | 2001-08-24 | 2001-08-24 | Process for refining meloxicam |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1098265C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20041918A1 (en) * | 2004-10-11 | 2005-01-11 | A M S A Anonima Materie Sintetiche Affini Spa | MELOXICAM PURIFICATION PROCESS |
| GB2443891B (en) * | 2006-11-20 | 2009-04-08 | Norbrook Lab Ltd | Process for the purification of meloxicam |
| CN103772378B (en) * | 2014-01-26 | 2016-02-24 | 悦康药业集团有限公司 | Meloxicam compound and tablet thereof |
-
2001
- 2001-08-24 CN CN 01128086 patent/CN1098265C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1342650A (en) | 2002-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107501045B (en) | Method for separating and purifying butanetriol from fermentation liquor by using macroporous adsorption resin | |
| CN111686694B (en) | MIL-101 material preparation method and application | |
| CN101948494B (en) | Method for extracting cobamamide | |
| CN1098265C (en) | Process for refining meloxicam | |
| CN1257182C (en) | Method for preparing enoxolone | |
| CN102850411A (en) | Preparation method of D-glucosamine sulfate potassium chloride salt | |
| CN101787036B (en) | High-purity cefamandole sodium compound | |
| CN102731502A (en) | Preparation method of carbpenem antibiotic | |
| CN102731506A (en) | Preparation method of ertapenem and its sodium salt | |
| CN106749258B (en) | Method for purifying ertapenem sodium | |
| CN101941983A (en) | Preparation method of high-purity cefoxitin sodium | |
| CN102731504A (en) | Preparation method of meropenem | |
| CN102603603B (en) | Method for preparing (S)-oxiracetam | |
| CN101665455B (en) | Method for preparing isooctyl thioglycolate by adopting tail liquid in the production process of O-alkyl-N-alkyl sulfide expelling carbamate | |
| CN101412710B (en) | Omeprazole sodium compound and preparation thereof | |
| CN102617327B (en) | Dexibuprofen compound and preparation method thereof | |
| CN109735713B (en) | Method for adsorbing and separating indium by using metal organic framework material UiO-66 | |
| CN109081777B (en) | Method for recovering and treating tetrafluorobenzoic acid wastewater | |
| CN113087630A (en) | Method for recycling and applying perindopril intermediate resolving agent (R) - (+) -alpha-phenylethylamine | |
| CN113045611A (en) | Preparation method of high-purity lincomycin hydrochloride | |
| CN113274975A (en) | Chloride ion adsorbent and preparation method and application method thereof | |
| CN105819444A (en) | Composite type activated carbon and application thereof in purifying tacrolimus | |
| CN1304407C (en) | Azithromycin refining process | |
| CN110028486B (en) | Method for extracting duloxetine intermediate | |
| CN102649771A (en) | Method of preparing capsaicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |